Biocon

  • BusinessTata Capital Growth to invest Rs 225 cr in Biocon Biologics

    Tata Capital Growth to invest Rs 225 cr in Biocon Biologics

    Bengaluru: Tata Capital Growth Fund will invest Rs 225 crore in Biocon Biologics India Ltd for an equity stake of 0.85 per cent. In a regulatory filing on Friday, Biocon Ltd said that…

  • Businessbiocon

    Biocon chief hails promise on ending tax harassment

    Bengaluru: Biocon Chairperson Kiran Mazumdar-Shaw on Saturday lauded Union Finance Minister Nirmala Sitharaman for promising to end tax harassment of India Inc and changing the Companies Act to decriminalise many non-compliances. “FM…

  • Business

    Biocon’s Biologics drug products facility gets a nod from US FDA

    Bengaluru: Biopharmaceuticals major Biocon Ltd said on Tuesday it has received an establishment inspection report from the US Food and Drug Administration (FDA) for its biologics drug product facility here, reaffirming its…

  • Bangalore

    Biocon cuts insulin price 50% in ‘poor’ countries

    Bengaluru: Biocon Biologics reduced the retail price of its recombinant human insulin 50 per cent in the low-and-middle income countries, the biotech major said on Friday. “We will offer the anti-diabetic drug…

  • Health

    Biocon to make 3 generic drugs in China

    Bengaluru: Biotechnology major Biocon would make three generic drugs for hard-selling in China through partnership, the company said on Saturday. “We have signed an agreement with the subsidiary of China Medical System Holdings…

  • Business

    Biocon Q1 net profit gallops 72 pc to Rs 206 crore

    Bengaluru: Biopharmaceutical major Biocon has reported 72 per cent jump in its consolidated net profit at Rs 206 crore during the quarter ended June 30 as opposed to Rs 120 crore during…

  • Business

    Biocon facilities receive European regulatory nod

    Bengaluru: The European Medicines Agency (EMA) has certified the Biocon drug product and substance facilities in the city’s southern suburb for good manufacturing practice. “We have received a certificate from EMA for…

  • Business

    Biocon to soon market breast cancer drug in Canada

    Bengaluru: Biotech major Biocon on Wednesday said it would soon market in Canada its anti-breast cancer drug Ogivri, which it co-developed with the US-based Mylan, following approval by the Canadian health regulator.…

Back to top button